QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
NASDAQ:DRRX

DURECT (DRRX) Stock Price, News & Analysis

$0.87
-0.04 (-4.26%)
(As of 05:21 PM ET)
Today's Range
$0.85
$0.94
50-Day Range
$0.77
$1.37
52-Week Range
$0.47
$7.46
Volume
114,542 shs
Average Volume
192,608 shs
Market Capitalization
$27.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.50

DURECT MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
3,036.8% Upside
$27.50 Price Target
Short Interest
Healthy
3.55% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.19
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.04) to ($0.75) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.36 out of 5 stars

Medical Sector

285th out of 918 stocks

Pharmaceutical Preparations Industry

119th out of 419 stocks

DRRX stock logo

About DURECT Stock (NASDAQ:DRRX)

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

DRRX Stock Price History

DRRX Stock News Headlines

Durect: Q4 Earnings Insights
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
DURECT Corp. Q4 Loss decreases, beats estimates
DURECT Q4 2023 Earnings Preview
The “Perfect Storm” for Gold
Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.
DRRX Apr 2024 5.000 call
DRRX Apr 2024 0.500 put
DRRX Mar 2024 1.500 put
DURECT: Reading Into AHFIRM Mortality Rates
Recap: Durect Q3 Earnings
Durect Corp DRRX
4DRRX : Durect Earnings Preview
JonesTrading Downgrades Durect (DRRX)
See More Headlines
Receive DRRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2021
Today
4/19/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:DRRX
Employees
58
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$27.50
High Stock Price Target
$41.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+3,036.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-27,620,000.00
Net Margins
-323.16%
Pretax Margin
-323.16%

Debt

Sales & Book Value

Annual Sales
$8.55 million
Book Value
$0.50 per share

Miscellaneous

Free Float
29,701,000
Market Cap
$27.21 million
Optionable
Optionable
Beta
0.85
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. James E. Brown D.V.M. (Age 67)
    Co-Founder, CEO, President & Director
    Comp: $633.46k
  • Mr. Timothy M. Papp M.B.A. (Age 48)
    CFO & Secretary
    Comp: $427.62k
  • Dr. Norman L. Sussman M.D. (Age 71)
    Chief Medical Officer
    Comp: $471.71k
  • Ms. Judy R. Joice (Age 67)
    Senior Vice President of Operations & Corporate Quality Assurance
    Comp: $451.82k
  • Dr. WeiQi Lin M.D.
    Ph.D., Executive VP of Research & Development and Principal Scientist
  • Mr. Keith L. Lui M.B.A.
    Senior Vice President of Business Development, Commercial & Medical Affairs
  • Ms. Jian Li M.B.A. (Age 54)
    Senior VP of Finance, Corporate Controller & Secretary
    Comp: $297.08k
  • Dr. Su Il Yum Ph.D. (Age 85)
    Executive Officer
    Comp: $331.74k

DRRX Stock Analysis - Frequently Asked Questions

Should I buy or sell DURECT stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last twelve months. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" DRRX shares.
View DRRX analyst ratings
or view top-rated stocks.

What is DURECT's stock price target for 2024?

5 Wall Street research analysts have issued 12-month price objectives for DURECT's stock. Their DRRX share price targets range from $5.00 to $41.00. On average, they expect the company's stock price to reach $27.50 in the next twelve months. This suggests a possible upside of 3,036.8% from the stock's current price.
View analysts price targets for DRRX
or view top-rated stocks among Wall Street analysts.

How have DRRX shares performed in 2024?

DURECT's stock was trading at $0.59 at the beginning of 2024. Since then, DRRX shares have increased by 48.6% and is now trading at $0.8767.
View the best growth stocks for 2024 here
.

When is DURECT's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our DRRX earnings forecast
.

How were DURECT's earnings last quarter?

DURECT Co. (NASDAQ:DRRX) announced its quarterly earnings results on Monday, November, 1st. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.10. The specialty pharmaceutical company earned $2.17 million during the quarter, compared to analyst estimates of $2.18 million. DURECT had a negative trailing twelve-month return on equity of 316.78% and a negative net margin of 323.16%. During the same quarter in the previous year, the firm posted ($0.50) EPS.

When did DURECT's stock split?

Shares of DURECT reverse split before market open on Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of DURECT own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM).

How do I buy shares of DURECT?

Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DRRX) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners